Advani RH, Flinn I, Popplewell L, et al. Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. J Clin Oncol 36, 2018 (suppl; abstr 7504)
Three-year Safety of Radium-223 in Patients with mCRPC and Symptomatic Bone Metastases
jul 2017 | Uro-oncologie